0001140361-17-022461.txt : 20170526 0001140361-17-022461.hdr.sgml : 20170526 20170526132355 ACCESSION NUMBER: 0001140361-17-022461 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170525 FILED AS OF DATE: 20170526 DATE AS OF CHANGE: 20170526 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SULLIVAN LOUIS W CENTRAL INDEX KEY: 0001193522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 17873097 FORMER NAME: FORMER CONFORMED NAME: SULLIVAN LOUIS DATE OF NAME CHANGE: 20020927 4 1 doc1.xml FORM 4 X0306 4 2017-05-25 0 0001367644 Emergent BioSolutions Inc. EBS 0001193522 SULLIVAN LOUIS W 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 1 0 0 0 Common Stock 2016-08-01 4 J 0 152 0 A 34637 D Common Stock 2016-08-01 4 J 0 604 0 A 35241 D Common Stock 2016-08-01 4 J 0 577 0 A 35818 D Common Stock 2017-05-25 4 A 0 8259 0.00 A 40077 D Employee Stock Option (Right to buy) 14.71 2016-08-01 4 J 0 693 0 A 2020-05-20 Common Stock 7893 7893 D Employee Stock Option (Right to buy) 20.08 2016-08-01 4 J 0 693 0 A 2021-05-19 Common Stock 7893 7893 D Employee Stock Option (Right to buy) (Common Stock) 13.37 2016-08-01 4 J 0 693 0.00 A 2019-05-17 Common Stock 7893 7893 D Employee Stock Option (Right to buy) (Common Stock) 13.00 2016-08-01 4 J 0 693 0.00 A 2020-05-23 Common Stock 7893 7893 D Employee Stock Option (Right to buy) (Common Stock) 18.64 2016-08-01 4 J 0 905 0.00 A 2017-05-22 2021-05-22 Common Stock 10305 10305 D In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017. In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018. In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019. Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. The option grant is fully vested. /s/ Eric Burt, Attorney-in-fact 2017-05-26